Clinical Trial

Circulating Tumor DNA

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a single-arm, phase II study examining elacestrant in the adjuvant treatment of patients with ER+ breast cancer who test positive for circulating tumor DNA (ctDNA) during the screening period of the trial. Our trial will proceed in three separate phases: screening, treatment, and follow-up.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2025-04-03; most recent amendment 2026-06-25.
Status change: Not Yet Recruiting → Recruiting 2025-07-28
Trial Details
NCT Number NCT06923527
Lead Sponsor Yale University
Collaborators: Johns Hopkins University, Stemline Therapeutics, Inc.
Conditions ER+ Breast Cancer
Enrollment 50 participants
Start Date 2025-09-30
Primary Completion 2027-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-06-29